David Planchard
Gustave Roussy thoracic oncologist on the IFCT board, widely published on BRAF- and EGFR-targeted therapy in lung cancer.
Overview
David Planchard is a medical oncologist at Gustave Roussy (Villejuif) and a member of the IFCT board. He has led or co-led pivotal trials of targeted agents in oncogene-driven non-small cell lung cancer, including BRAF V600E-mutant disease, and contributes to ESMO clinical practice guidelines for metastatic NSCLC.
Pages like this
not linked directly; found by shared links- PersonAlexis Cortot
Shares Intergroupe Francophone de Cancérologie Thoracique, Non-small-cell lung cancer and the tags clinician-scientist, lung cancer.
- PersonShun Lu
Shares Non-small-cell lung cancer and the tags clinician-scientist, lung cancer, targeted therapy.
- PersonFabrice Barlesi
Shares Intergroupe Francophone de Cancérologie Thoracique, Non-small-cell lung cancer.
- PersonSuresh S. Ramalingam
Shares Non-small-cell lung cancer and the tags clinician-scientist, lung cancer, targeted therapy.
- PersonHidetoshi Hayashi
Shares Non-small-cell lung cancer and the tags clinician-scientist, lung cancer.
- PersonMartin Schuler
Shares Non-small-cell lung cancer and the tags clinician-scientist, lung cancer.
- PersonCaicun Zhou
Shares Non-small-cell lung cancer and the tags clinician-scientist, lung cancer.
- PersonMatthias Guckenberger
Shares Non-small-cell lung cancer and the tags clinician-scientist, lung cancer.